Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of First-Line Veliparib and Carboplatin-Paclitaxel in Patients With HER2− Advanced Germline BRCA+ Breast Cancer: Subgroup Analysis of a Randomised Clinical TrialEur. J. Cancer 2021 Sep 01;154(xx)35-45, BK Arun, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, SL Puhalla, KM Bell-McGuinn, BA Bach, MG Kundu, CK Ratajczak, D Maag, V Diéras
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.